The effect of immunomodulator azoximer bromide on immunoglobulin levels in children with newly diagnosed tuberculosis

Abstract

Aim. To analyze the effect of the immunomodulator azoximer bromide on serum immunoglobulins (IgE, A, M, G) in the complex treatment for children with newly diagnosed tuberculosis. Materials and methods. The study was included 51 with newly diagnosed tuberculosis children, which were divided into 2 groups: 26 children suffer from disease, who received immunomodulator azoximer bromide (main group) in combination treatment with antimycobacterial therapy (AMBT) and 25 children suffer from disease who received AMBT only (control group). The comparison group included 30 healthy children. The children from the main group on the background of standard AMBT additionally were used the azoximer bromide (immunomodulator) to correct immunological changes: in children under 10 years of age, 6 mg twice a day, in children over 10 years – 12 mg twice a day; course of treatment – 14 days. Research indicators such as IgE, A, M, G in serum were performed on the basis of the Immunological Department in the Training Medical and Laboratory center of ZSMU by solid-phase enzyme-linked immunosorbent assay (ELISA) using a device enzyme-linked immunosorbent reader Sirio S using reagent kits LTD RPL “Granum” (Kharkiv), units of measurement: IgE – IU/ml), IgA, M, G – g/l. The study was conducted at the beginning of intensive phase (IF) AMBT and at the end of the AMBT maintenance phase (MF). The study results were processed on a personal computer using the statistical package of the licensed program Statistica, version 13 (Copyright 1984–2018 TIBCO Software Inc. All rights reserved, License No. JPZ8041382130ARCN10-J). Results. Children with newly diagnosed tuberculosis, who received immunomodulator azoximer bromide in combination therapy, after the end of the AMBT MF was determined by the normalization of serum IgA levels (1.22 (0.75; 1.74) g/l against 1.70 (1.11; 2.01) g/l, P < 0.02), which was 1.4 times lower than children who received only AMBT. The levels of IgE and M throughout the course of treatment were within the age norm with decreasing at the end of treatment, and the level of IgG throughout the course of treatment remained significantly higher than that of the healthy children group. Children with newly detected tuberculosis who received only AMBT, after the end of AMBT MF on the background of normal levels of IgE and M, the level of IgA remained significantly higher in 1.4 times, and the level of IgG tended to increase. Conclusions. Considering the obtained results, children with newly detected tuberculosis, who received of the immunomodulator azoximer bromide in complex treatment, helped to normalize of IgA level in serum, after completion of treatment. Therefore, the effect of the immunomodulator azoximer bromide in the complex therapy of children with newly detected tuberculosis on immunoglobulin indicators were significant, which would improve the effectiveness of antimycobacterial therapy in this contingent of patients in general.